Search Results - "Sholl, L.M."

Understanding patterns of pathologic response following neoadjuvant immunotherapy for solid tumors by Sholl, L.M.

Get full text

Clinicopathological and genomic correlates of programmed cell death ligand 1 (PD-L1) expression in nonsquamous non-small-cell lung cancer by Lamberti, G., Spurr, L.F., Li, Y., Ricciuti, B., Recondo, G., Umeton, R., Nishino, M., Sholl, L.M., Meyerson, M.L., Cherniack, A.D., Awad, M.M.

“…Programmed cell death ligand 1 (PD-L1) tumor proportion score (TPS) is the primary clinically-available biomarker of response to immunotherapy in…”
Get full text

Intrathymic cyst: Clinical and radiological features in surgically resected cases by Araki, T, Sholl, L.M, Gerbaudo, V.H, Hatabu, H, Nishino, M

“…Aim To investigate radiological and clinical characteristics of pathologically proven cases of intrathymic cysts. Materials and methods The study population…”
Get full text

Patterns of metastasis and recurrence in thymic epithelial tumours: longitudinal imaging review in correlation with histological subtypes by Khandelwal, A, Sholl, L.M, Araki, T, Ramaiya, N.H, Hatabu, H, Nishino, M

“…Aim To determine the patterns of metastasis and recurrence in thymic epithelial tumours based on longitudinal imaging studies, and to correlate the patterns…”
Get full text

Outcomes to first-line pembrolizumab in patients with non-small-cell lung cancer and very high PD-L1 expression by Aguilar, E.J., Ricciuti, B., Gainor, J.F., Kehl, K.L., Kravets, S., Dahlberg, S., Nishino, M., Sholl, L.M., Adeni, A., Subegdjo, S., Khosrowjerdi, S., Peterson, R.M., Digumarthy, S., Liu, C., Sauter, J., Rizvi, H., Arbour, K.C., Carter, B.W., Heymach, J.V., Altan, M., Hellmann, M.D., Awad, M.M.

“…In non-small-cell lung cancers with programmed death-ligand 1 (PD-L1) expression on ≥50% of tumor cells, first-line treatment with the PD-1 inhibitor…”
Get full text

PD-L1 expression, tumor mutational burden, and response to immunotherapy in patients with MET exon 14 altered lung cancers by Sabari, J.K., Leonardi, G.C., Shu, C.A., Umeton, R., Montecalvo, J., Ni, A., Chen, R., Dienstag, J., Mrad, C., Bergagnini, I., Lai, W.V., Offin, M., Arbour, K.C., Plodkowski, A.J., Halpenny, D.F., Paik, P.K., Li, B.T., Riely, G.J., Kris, M.G., Rudin, C.M., Sholl, L.M., Nishino, M., Hellmann, M.D., Rekhtman, N., Awad, M.M., Drilon, A.

“…MET exon 14 alterations are actionable oncogenic drivers. Durable responses to MET inhibitors are observed in patients with advanced MET exon 14-altered lung…”
Get full text

1060P Impact of baseline clinicopathologic and genomic features on outcomes to KRAS G12C inhibitors in patients with NSCLC by Lamberti, G., Cooper, A.J., Ricciuti, B., Alessi, J.V., de Castro Barrichello, A.P., Pecci, F., Vaz, V.R., Nishino, M., Sholl, L.M., Heist, R., Awad, M.

Get full text

Molecular markers of metastatic disease in KRAS-mutant lung adenocarcinoma by Boiarsky, D., Lydon, C.A., Chambers, E.S., Sholl, L.M., Nishino, M., Skoulidis, F., Heymach, J.V., Luo, J., Awad, M.M., Janne, P.A., Van Allen, E.M., Barbie, D.A., Vokes, N.I.

“…Prior studies characterized the association of molecular alterations with treatment-specific outcomes in KRAS-mutant (KRASMUT) lung adenocarcinoma (LUAD). Less…”
Get full text

Radiological features and metastatic patterns of thymic neuroendocrine tumours by Araki, T., Sholl, L.M., Hatabu, H., Nishino, M.

“…To investigate the clinical and image features of thymic neuroendocrine tumours (NETs), and characterise the radiological patterns of recurrence and metastasis…”
Get full text

Dissecting the clinicopathologic, genomic, and immunophenotypic correlates of KRASG12D-mutated non-small-cell lung cancer by Ricciuti, B., Alessi, J.V., Elkrief, A., Wang, X., Cortellini, A., Li, Y.Y., Vaz, V.R., Gupta, H., Pecci, F., Barrichello, A., Lamberti, G., Nguyen, T., Lindsay, J., Sharma, B., Felt, K., Rodig, S.J., Nishino, M., Sholl, L.M., Barbie, D.A., Negrao, M.V., Zhang, J., Cherniack, A.D., Heymach, J.V., Meyerson, M., Ambrogio, C., Jänne, P.A., Arbour, K.C., Pinato, D.J., Skoulidis, F., Schoenfeld, A.J., Awad, M.M., Luo, J.

“…Allele-specific KRAS inhibitors are an emerging class of cancer therapies. KRAS-mutant (KRASMUT) non-small-cell lung cancers (NSCLCs) exhibit heterogeneous…”
Get full text

Acquired Resistance to KRASG12C Inhibition in Cancer by Awad, Mark M, Liu, Shengwu, Rybkin, Igor I, Arbour, Kathryn C, Dilly, Julien, Zhu, Viola W, Johnson, Melissa L, Heist, Rebecca S, Patil, Tejas, Riely, Gregory J, Jacobson, Joseph O, Yang, Xiaoping, Persky, Nicole S, Root, David E, Lowder, Kristen E, Feng, Hanrong, Zhang, Shannon S, Haigis, Kevin M, Hung, Yin P, Sholl, Lynette M, Wolpin, Brian M, Wiese, Julie, Christiansen, Jason, Lee, Jessica, Schrock, Alexa B, Lim, Lee P, Garg, Kavita, Li, Mark, Engstrom, Lars D, Waters, Laura, Lawson, J. David, Olson, Peter, Lito, Piro, Ou, Sai-Hong I, Christensen, James G, Jänne, Pasi A, Aguirre, Andrew J

“…A study involving 38 patients who initially had a response to adagrasib or who had a long period of stable disease in response to the drug but then had…”
Get full text

1180PDGENOMIC CHANGES IN LUNG CANCER PATIENTS WITH MULTIPLE LUNG RELAPSES by Calles, A., Thorner, A.R., Sholl, L.M., Butaney, M., Capelletti, M., Mentzer, S.J., van Hummelen, P., Janne, P.A.

“…Abstract Aim: Patients with early stage non-small cell lung cancer (NSCLC) undergo surgical removal of their tumors. However, in some individuals tumors can…”
Get full text

Genomic Changes in Lung Cancer Patients with Multiple Lung Relapses by Calles, A., Thorner, A.R., Sholl, L.M., Butaney, M., Capelletti, M., Mentzer, S.J., van Hummelen, P., Janne, P.A.

Get full text